



**HAL**  
open science

## **Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia**

Cedric Le May, Sanae Kourimate, Cédric Langhi, Maud Chétiveaux, Anne Jarry, Christine Coméra, Xavier Collet, Folkert Kuipers, Michel Krempf, Bertrand Cariou, et al.

### ► To cite this version:

Cedric Le May, Sanae Kourimate, Cédric Langhi, Maud Chétiveaux, Anne Jarry, et al.. Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 2009, 29 (5), pp.684-690. 10.1161/ATVBAHA.108.181586 . hal-02661775

**HAL Id: hal-02661775**

**<https://hal.inrae.fr/hal-02661775>**

Submitted on 30 May 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# Proprotein Convertase Subtilisin Kexin Type 9 Null Mice Are Protected From Postprandial Triglyceridemia

Cédric Le May, Sanae Kourimate, Cédric Langhi, Maud Chétiveaux, Anne Jarry, Christine Comera, Xavier Collet, Folkert Kuipers, Michel Krempf, Bertrand Cariou, Philippe Costet

**Objectives**—Proprotein convertase subtilisin kexin type 9 (PCSK9) is a natural inhibitor of the low-density lipoprotein receptor, and its deficiency in humans results in low plasma LDL-cholesterol and protection against cardiovascular disease. We explored whether PCSK9 expression impacts postprandial triglyceridemia, another important cardiovascular risk factor.

**Methods and Results**—Real-time PCR and confocal microscopy were used to show that PCSK9 is expressed throughout the entire small intestine and in human enterocytes. On olive oil gavage, PCSK9-deficient mice showed a dramatically decreased postprandial triglyceridemia compared with their wild-type littermates. Lymph analysis revealed that intestinal TG output is not quantitatively modified by PCSK9 deletion. However, PCSK9<sup>-/-</sup> mice present with a significant reduction of lymphatic apoB secretion compared to PCSK9<sup>+/+</sup> mice. Modulating PCSK9 expression in polarized CaCo-2 cells confirmed the relationship between PCSK9 and apoB secretion; PCSK9<sup>-/-</sup> mice consistently secrete larger TG-rich lipoprotein than wild-type littermates. Finally, kinetic studies showed that PCSK9-deficient mice have an increased ability to clear chylomicrons compared to wild-type littermates.

**Conclusion**—These findings indicate that in addition to its effect on LDL-cholesterol, PCSK9 deficiency might protect against cardiovascular disease by reducing postprandial triglyceridemia. (*Arterioscler Thromb Vasc Biol.* 2009;29:684-690.)

**Key Words:** PCSK9 ■ chylomicron ■ postprandial ■ intestine ■ CaCo-2

Gain-of-function mutations affecting proprotein convertase subtilisin/kexin type 9 (PCSK9) are associated with autosomal dominant hypercholesterolemia and premature atherosclerosis.<sup>1</sup> It is now established that PCSK9 is a natural inhibitor of the low-density lipoprotein receptor (LDLr), acting posttranscriptionally.<sup>2</sup> Circulating PCSK9 binds to the EGF-A extracellular domain of the hepatic LDLr and prevents its recycling to the cell surface.<sup>3</sup>

A breakthrough study reported that blacks harboring PCSK9 loss-of-function mutations had an 88% risk reduction for coronary heart disease.<sup>4</sup> Although the lower concentrations of LDL cholesterol over one's lifetime is suggested to be the main reason for this very high level of protection, we hypothesized that PCSK9 deficiency might also affect other risk factors. Low levels of HDL cholesterol (HDL-c) and elevated nonfasted triglycerides (TG) levels are associated with increased risk for cardiovascular disease. No association between PCSK9 loss-of-function mutations and plasma HDL-c levels has been noticed.<sup>4,5</sup> However, to our knowledge, nonfasting plasma TG were not measured in PCSK9-deficient individuals. They are an important contributor to the risk for cardiovascular disease.<sup>6,7</sup>

Rashid et al reported the phenotype of PCSK9-deficient mice (PCSK9<sup>-/-</sup>) mice and observed that they exhibit lower plasma cholesterol levels (-50%) and are hypersensitive to statins.<sup>8</sup> The potential role of PCSK9 in the intestine in mice and humans remains unexplored.

During the postprandial period, dietary lipids are actively absorbed into the enterocyte. After intracellular reesterification, long chain fatty acids and cholesterol esters are associated with phospholipids and apolipoproteins, particularly apoB48, to produce TG-rich lipoproteins, mainly chylomicrons.<sup>9</sup>

Chylomicrons are secreted into the mesenteric lymph to eventually deliver lipids to the peripheral tissues and organs.<sup>9</sup> It is believed that the number of chylomicrons does not change during the postprandial phase, but their size increases because of their TG enrichment.<sup>10</sup> Because a single copy of apoB48 is present per chylomicron,<sup>11</sup> the intestinal output of apoB remains constant during the absorptive process. ApoB48 is the preferred protein for the intestine to coat chylomicrons in mice.<sup>12</sup> Chylomicron remnants are cleared from the blood by the LDLr and the LDLr-related protein

Received November 25, 2008; revision accepted February 18, 2009.

From the INSERM U915 (C.L.M., S.K., C.L., M.C., M.K., B.C., P.C.), CHU de Nantes, France; Université de Nantes, EA Biometadys (A.J.), Nantes, France; INSERM U563 (C.C., X.C.), Toulouse, France; the Center for Liver, Digestive, and Metabolic Diseases (F.K.), University of Groningen, The Netherlands; Université de Nantes, l'institut du thorax (M.K., B.C.), Clinique d'Endocrinologie et Nutrition, Nantes, France; the Centre de Recherche en Nutrition Humaine de Nantes (M.K., P.C.), Nantes, France; and INRA UR66 (C.C.), France.

Correspondence to Philippe Costet, INSERM U915, CHU Hôtel Dieu, 3ENORD, 9, Quai Moncoussu, 44000, Nantes, France. E-mail philippe.costet@univ-nantes.fr

© 2009 American Heart Association, Inc.

*Arterioscler Thromb Vasc Biol* is available at <http://atvb.ahajournals.org>

DOI: 10.1161/ATVBAHA.108.181586

Comment citer ce document: 684

Le May, C, Kourimate, S., Langhi, C., Chetiveaux, M., Jarry, A., Comera, C., Collet, X., Kuipers, F., Krempf, M., Cariou, B., Costet, P. (2009). Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia. *Arteriosclerosis, Thrombosis, and*

(LRP).<sup>13</sup> PCSK9-deficient mice display an increase in hepatic LDLr protein, but not in LRP.<sup>8</sup>

Our aim was to determine PCSK9 localization in murine and human intestines and to determine its role in postprandial lipemia. The main outcome is that PCSK9 deficiency results in dramatically less plasma TG accumulation in 14 hour-fasted mice, challenged with an olive oil gavage, because of increased hepatic clearance of larger chylomicrons.

## Methods

An expanded Methods section can be found in the supplemental materials (available online at <http://atvb.ahajournals.org>).

### Human Tissues

The human tissue fragments were processed according to the French Guidelines for Research on Human Tissues.<sup>14</sup> Informed patient consent was obtained, according to the French bioethics law.<sup>15</sup> A detailed protocol and information concerning patients are available in the supplemental materials.

### Animals

PCSK9<sup>+/-</sup> mice were purchased from Jackson Laboratories (Bar Harbor, Me), interbred to produce PCSK9<sup>-/-</sup> and PCSK9<sup>+/+</sup> (wild-type [wt]) littermates, and genotyped as described elsewhere.<sup>8</sup> Mice had free access to food and water under a 12-hour light/12-hour dark cycle in a temperature-controlled environment. All animal studies were conducted with age-matched male mice (2-month-old), and approved by the Unité de Thérapeutique Expérimentale (Agreement No. BP44015). Before surgery, mice were anesthetized with a single intraperitoneal injection of 100  $\mu$ L of ketamin/ivermectine (Imalgène 1000, Merial).

### Statistics


Each experiment was representative of at least 2 independent experiments with a minimum of triplicates per condition. Values are reported as means  $\pm$  SEM. Statistical significance was analyzed using a Student unpaired *t* test. Values of *P* < 0.05 were considered as significant.

## Results

### PCSK9 Is Expressed in the Small Intestine of Mice and Humans

Using real-time quantitative PCR, we first examined PCSK9 and the LDLr mRNA quantities along the gastrointestinal tract in mice (Figure 1A). PCSK9 expression in the stomach was virtually undetectable. However, PCSK9 was expressed throughout the small intestine and colon, at a level which did not vary significantly along the intestinal cephalo-caudal axis, and which was similar to that in the liver (Figure 1A). As previously published,<sup>17</sup> the LDLr was abundantly expressed along the digestive tract.

Using confocal microscopy, we determined for the first time the localization of PCSK9 protein in frozen sections of normal, human, small intestines. PCSK9 was expressed almost exclusively in the epithelial barrier of the human duodenum and ileum, both in enterocytes and goblet cells (Figure 1B). PCSK9 immunostaining was observed in the cytoplasm of epithelial cells and accumulated at the apical and basolateral sides of the cells (Figure 1B). Blocking of the PCSK9 antibody with an excess of antigen peptide abolished the staining (Figure 1B, upper panel, right), confirming the specificity of the antibody. We also examined the localization of PCSK9 in the human colonic, enterocyte-like cell line,



**Figure 1.** PCSK9 is highly expressed in the small intestine and enterocytes. A, Real-time PCR measurement of PCSK9, LDLr gene expression in PCSK9<sup>+/+</sup> mice. B, Immunofluorescence staining in human duodenum and ileum, and CaCo-2. See also supplement Methods.

CaCo-2, maintained as polarized by culturing on filters. As shown in Figure 1B (lower panel), the xy image (left) shows a punctuated staining within CaCo-2 cells, and the xz image (right) shows a strong PCSK9 immunostaining mainly in the apical compartment of the cells.

### PCSK9 Is Upregulated by Pravastatin in CaCo-2 Cells and the LDLr Expression Is Increased in Intestines of PCSK9<sup>-/-</sup> Mice


We next examined whether PCSK9 is upregulated by statins in CaCo-2 cells as it has been reported in hepatocytes<sup>18,19</sup> (supplemental Figure IA). We exposed the cells for 48 hours to 10  $\mu$ mol/L pravastatin and observed a 160% increase in PCSK9 mRNA, and a 110% increase in LDLr mRNA (supplemental Figure IA). We next confirmed that the LDLr content is increased in the liver of PCSK9<sup>-/-</sup> mice compared to wt littermates, and observed a similar phenotype in the medial intestine (+621%, *P* < 0.05; supplemental Figure IB).

### PCSK9 Deficiency Protects Mice Against Postprandial Lipemia

Random-fed PCSK9<sup>-/-</sup> mice had lower total cholesterol than wt littermates (-35% in 3-month-old mice, *P* < 0.001), and similar plasma TG concentrations (supplemental Figure IIA). Plasma TG levels were measured over a 4-hour period in 14 hour-fasted mice after they received an intragastric bolus of olive oil (200  $\mu$ L; Figure 2). At T0, plasma levels of TG were comparable between PCSK9<sup>+/+</sup> and PCSK9<sup>-/-</sup> mice. Two hours after gavage, PCSK9<sup>+/+</sup> mice showed a 209% increase in plasma TG, whereas PCSK9<sup>-/-</sup> littermates displayed a

Comment citer ce document :

Le May, C, Kourimate, S., Langhi, C., Chetiveaux, M., Jarry, A., Comera, C., Collet, X., Kuipers, F., Krempf, M., Cariou, B., Costet, P. (2009). Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia. Arteriosclerosis, Thrombosis, and



**Figure 2.** Postprandial lipemia is reduced in PCSK9<sup>-/-</sup> mice. 14 hour-fasted PCSK9<sup>+/+</sup> (white circles, n=12 mice) and PCSK9<sup>-/-</sup> littermates (black circles, n=14 mice) received an intragastric olive oil load. Blood samples were collected before gavage (time 0) and at 1, 2, 3, and 4 hours after gavage and plasma triglycerides concentrations determined. \*\**P*<0.01.

strongly attenuated TG postprandial response. Mean TG appearance rates were, respectively,  $0.19 \pm 0.032$  and  $0.082 \pm 0.022$  g/L/h for PCSK9<sup>+/+</sup> and PCSK9<sup>-/-</sup> mice, ie, 62% less (n=12 PCSK9<sup>+/+</sup> and n=14 PCSK9<sup>-/-</sup> mice from 2 independent experiments).

Fractionation by fast protein liquid chromatography (FPLC) showed that the difference in triglyceridemia observed 2 hours after gavage was attributable to a decrease in the TG content of chylomicrons/VLDL lipoproteins (supplemental Figure IIB and supplemental Methods and Results).

### Gastric Emptying, Intestinal Transit, and Fat Absorption After Oral Oil Challenge

The defect in postprandial lipemia observed in PCSK9<sup>-/-</sup> mice could be attributable to (1) decreased intestinal lipid absorption, or chylomicron production, or (2) accelerated lipolysis or clearance of TG-rich lipoproteins. We first measured the radioactivity content of intestinal segments of PCSK9<sup>+/+</sup> and PCSK9<sup>-/-</sup> littermates 2 hours after a gavage with olive oil containing <sup>3</sup>H-triolein (Figure 3A). Triolein is a triglyceride and unsaturated fat formed from oleic acid, the main constituent of olive oil. This method reflects (1) the enterocytic uptake of <sup>3</sup>H-oleate, (2) the intracellular non esterified or reesterified <sup>3</sup>H-oleate, (3) the reuptake of radio-labeled nascent particles. PCSK9<sup>-/-</sup> mice had a tendency to accumulate less <sup>3</sup>H in the proximal and medial part of their intestine compared to wt mice, suggesting that lipid uptake could be defective in these segments. To determine intestinal fat absorption, we measured food intake and collected feces every 24 hours for 3 consecutive days. Food intake, weight of excreted feces, and fecal fat excretion were not significantly different between mice (supplemental Table II). PCSK9<sup>+/+</sup> and PCSK9<sup>-/-</sup> mice absorb fat with the same efficiency (Figure 3B) demonstrating that reduced lipemia in PCSK9<sup>-/-</sup> mice is not attributable to fat malabsorption. As a control, PCSK9<sup>+/+</sup> mice fed with orlistat, an inhibitor of pancreatic lipases, showed a 45% decrease in total fat absorption compared to PCSK9<sup>+/+</sup> mice under normal chow (Figure 3B).

Altered postprandial lipemia could also be attributable to gastric emptying or intestinal motility defect. We performed an oral gavage with a nonabsorbable 70-KDa FITC conjugated dextran marker diluted in olive oil. After 30 minutes, about 10% of the marker was still present in the stomach of PCSK9<sup>+/+</sup> and PCSK9<sup>-/-</sup> mice (Figure 3C), demonstrating that PCSK9 deficiency does not alter gastric emptying. Intestinal transit was also similar in both genotypes (Figure 3C).

Thus, although there was a trend toward less accumulation of <sup>3</sup>H-triolein in the proximal and medial intestine of PCSK9<sup>-/-</sup> mice after an olive oil gavage, they do not show a defect in fat absorption, gastric emptying or intestinal transit.

### Chylomicron Secretion in PCSK9<sup>-/-</sup> Mice

To directly explore the impact of PCSK9 deficiency on chylomicron output, we cannulated the lymph ducts from 2 hour-fasted PCSK9<sup>+/+</sup> and PCSK9<sup>-/-</sup> littermates. After establishing a 30-minute baseline collection, we injected a bolus of olive oil in their duodenum, and collected the lymph at timed intervals for 210 minutes (Figure 4A). Lymph flow was reduced by 20% in knockout mice ( $0.59 \mu\text{L}/\text{min}$  versus  $0.47 \mu\text{L}/\text{min}$ , *P*<0.05). No difference in cumulative TG contents was observed in the first 1.5 hour. In a second phase, the accumulation tended to be reduced in PCSK9<sup>-/-</sup> mice, although it did not reach significance (Figure 4A).

Lymph samples collected at various times after olive oil injection were pooled, and equal amounts were loaded on a gel for separation of the proteins by electrophoresis (Figure 4B). As expected, the quantity of apoB was relatively constant during the absorption process within each genotype, and apoB48 was more abundant than apoB100.<sup>10</sup> However, apoB100 and apoB48 contents were significantly lower in lymph from PCSK9<sup>-/-</sup> mice (-39%, *P*<0.05 and -40%, *P*<0.01), suggesting that PCSK9 deficiency results in less chylomicrons being secreted. The positive relation between PCSK9 expression and the apoB output was confirmed in CaCo-2 cells (supplemental Figure III and supplemental Methods and Results). We also determined the content of the other apolipoprotein by electrophoresis. No striking difference between genotypes was observed. There was a tendency toward an accumulation of apoE in lymph from PCSK9<sup>-/-</sup> mice (Figure 4C).


As lymphatic TG output was unchanged and lymphatic apoB secretion was decreased, it suggests that PCSK9<sup>-/-</sup> mice might secrete larger chylomicrons than wt littermates. Using dynamic light scattering techniques, we showed that chylomicron diameters from PCSK9<sup>-/-</sup> mice were increased by 10% compared to wt littermates (Figure 4D). Assuming that they are spherical particles, PCSK9<sup>-/-</sup> mice secrete chylomicrons with a volume at least 25% larger than PCSK9<sup>+/+</sup> mice (Figure 4D).

### Chylomicron Catabolism in PCSK9<sup>+/+</sup> and PCSK9<sup>-/-</sup> Mice

We next measured the hepatic TG content after olive oil gavage. There was no change in hepatic TG contents in fed PCSK9<sup>+/+</sup> and PCSK9<sup>-/-</sup> mice (Figure 5A). Fasting in-

Comment citer ce document :

Le May, C, Kourimate, S., Langhi, C., Chetiveaux, M., Jarry, A., Comera, C., Collet, X., Kuipers, F., Krempf, M., Cariou, B., Costet, P. (2009). Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia. Arteriosclerosis, Thrombosis, and



**Figure 3.** PCSK9<sup>-/-</sup> mice do not present with altered intestinal fat absorption. A, Radioactivity in intestinal segments of PCSK9<sup>+/+</sup> and PCSK9<sup>-/-</sup> mice (n=8 mice) 2 hours after gavage. B, Total fat absorption in mice on chow diet (n=18 mice). \*\*\**P*<0.001. C, Gastric emptying and intestinal transit (n=4 mice).

duced an accumulation of TG by 100% in both genotypes (*P*<0.01). Two hours after olive oil gavage, hepatic TG contents were similar to those of PCSK9<sup>+/+</sup> mice in the fed state, but remained elevated in PCSK9<sup>-/-</sup> mice. Consequently, there was 54% more TG in livers of knockout mice after gavage (*P*<0.05), suggesting that TG originated from olive oil fatty acids. To confirm this, <sup>3</sup>H-triolein diluted in olive oil was orally administered to fasted mice, and 2 hours later the amount of hepatic radioactivity was measured. PCSK9<sup>-/-</sup> mice exhibited almost 200% more radioactivity than wt littermates showing that the hepatic uptake of chylomicrons was increased in these mice (supplemental Figure IV).

We verified whether the clearance of chylomicrons is enhanced in knockout mice (Figure 5B). Chylomicrons obtained by mesenteric lymph duct cannulation of wt and knockout mice (chyl<sup>+/+</sup> and chyl<sup>-/-</sup>) were labeled with <sup>125</sup>I and injected into the circulatory systems of mice from both genotypes. To mimic the postprandial status, we injected chyl<sup>+/+</sup> in PCSK9<sup>+/+</sup> mice and chyl<sup>-/-</sup> in PCSK9<sup>-/-</sup> mice. Consistent with the phenotype observed in Figure 2, PCSK9<sup>-/-</sup> mice cleared chyl<sup>-/-</sup> 37% faster than PCSK9<sup>+/+</sup> cleared chyl<sup>+/+</sup> (*P*<0.05). We also performed the experiment crossing the donors and receivers. PCSK9<sup>-/-</sup> mice cleared chyl<sup>-/-</sup> 21% faster than PCSK9<sup>+/+</sup> mice did

(*P*<0.01). These results reflect probably the higher hepatic LDLr content observed in PCSK9<sup>-/-</sup> mice (supplemental Figure IB). Surprisingly, we observed (1) no difference in chyl<sup>+/+</sup> clearance rates between the genotypes; and (2) PCSK9<sup>-/-</sup> mice cleared chyl<sup>-/-</sup> 56% more efficiently than chyl<sup>+/+</sup> (*P*<0.001).

Taken together, these data showed that the reduced postprandial lipemia in PCSK9<sup>-/-</sup> mice is caused in part by increased hepatic uptake.


## Discussion

This study shows that PCSK9 is highly expressed in enterocytes and plays a critical role in postprandial lipemia in mice. We first determined the expression of PCSK9 in the gastrointestinal tract. We showed that in mice PCSK9 is expressed throughout the digestive tract and colon at levels equivalent to those found in the liver. In the human intestine, PCSK9 is localized in the cytoplasm probably in the endoplasmic reticulum and the golgi, and it accumulates at the subapical and basolateral compartments of the enterocyte. The heterogeneity of this cellular distribution depending on the intestinal segment considered is puzzling. PCSK9 is expressed at both the apical and basolateral pole in the duodenum, and mainly at the apical pole in the ileum. It is possible that PCSK9 is directed toward both poles of the enterocyte in the upper part of the small intestine, in relation with the absorptive process and the lipoprotein secretion, and only to the apical side in the ileum that secretes less lipoproteins. It appears that CaCo-2 cells would be more representative of an ileal enterocyte, in respect to PCSK9 cellular expression. Indeed, in differentiated CaCo-2 cells, most of the signal was concentrated at the apical side. We observed high levels of expression in the ileum where the bile acid reuptake takes place. Since we recently showed that bile acids repress PCSK9,<sup>20</sup> it is tempting to speculate that PCSK9 might play a role in their metabolism. We also observed some PCSK9 protein in goblet cells, although its function in this cell type remains unknown.

PCSK9-deficient mice clearly exhibited reduced postprandial lipemia after olive oil gavage. A balance study showed that intestinal fat absorption was not significantly different between genotypes, and that PCSK9 deficiency does not alter the gastric emptying and intestinal transit. We have no clear explanation concerning the trend toward a decrease of accumulation of <sup>3</sup>H-triolein in the proximal and medial segments of PCSK9<sup>-/-</sup> mice. It could explain the weak trend observed during lymph cannulation, with PCSK9<sup>-/-</sup> mice secreting less TG. Thus, it might reflect some aspects of PCSK9 function in the intestine, in relation or not with the strong phenotype observed concerning the intestinal apoB secretion and postprandial lipemia in PCSK9<sup>-/-</sup> mice. We investigated whether this phenotype could be attributable to chylomicron production or catabolism. We directly collected the mesenteric lymph after olive oil gavage. TG outputs in lymph were virtually similar in both genotypes. We observed a 20% reduction of lymph flow in PCSK9<sup>-/-</sup> mice. There is a large number of plausible causes for lymph flow reduction,<sup>21</sup> and more work is needed to determine which one is responsible for this phenotype. Direct measurement on lymph samples

Comment citer ce document :

Le May, C, Kourimate, S., Langhi, C., Chetiveaux, M., Jarry, A., Comera, C., Collet, X., Kuipers, F., Krempf, M., Cariou, B., Costet, P. (2009). Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triacylglyceridemia, Arteriosclerosis, and




**Figure 4.** Mesenteric lymph output, composition, and size. A, Plasma cumulative TG (n=10 mice each genotype). B, ApoB100, apoB48 in pooled lymph samples. C, ApoE, AI, All, apoCs in lymph samples (n=4 mice), collected after olive oil gavage (t=30 minutes). D, Lipoproteins size (nm) in lymph samples. \* $P < 0.05$ , \*\* $P < 0.01$ .

collected in mice after oil gavage revealed that PCSK9<sup>-/-</sup> mice secreted less apoB than wt littermates did. The reduction in lymph flow could not account for this, as it was estimated with equal amounts of lymph from both genotypes. Experiments in differentiated CaCo-2 cells confirmed that PCSK9 deficiency results in a decrease in apoB secretion. Interestingly, Rashid et al showed that primary hepatocytes from PCSK9<sup>-/-</sup> mice exhibit reduced apoB48 secretion.<sup>8</sup> However, on a high-fat diet, transient PCSK9 knockdown in mice led to a decrease in serum apoB100 content and an increase in apoB48 content, probably because of the upregulation of apobec1.<sup>22</sup> Apobec 1 is the enzyme responsible for the production of apoB48 in human intestine and is also expressed in rodent liver.<sup>23</sup> We did not observe a change in the ratio of apoB48 to apoB100 in lymph samples of PCSK9<sup>-/-</sup> and PCSK9<sup>+/+</sup> mice, suggesting that apobec1 is not involved in the differences we observed. The lower lymphatic apoB output in PCSK9<sup>-/-</sup> mice indicates that they secrete less chylomicrons. A direct measurement of their size showed an

average diameter 10% larger than that found in wild-type littermates. The corresponding 25% increase in volume could compensate for the lower number of particles and results in the absence of a significant difference concerning the resulting TG output. Another plausible explanation is the higher expression of LDLr we observed in the intestine of PCSK9<sup>-/-</sup> mice. In humans and rodents, LDLr is present at the basolateral side of enterocytes, and is able to efficiently capture LDL particles.<sup>17</sup> However, the functional importance of the LDLr in the intestine is unclear. In the liver, Twisk et al showed that the LDLr controls apoB secretion by promoting the reuptake of newly synthesized apoB containing lipoprotein particles.<sup>24</sup> We can speculate that intestinal TG-rich lipoproteins are more avidly recaptured in PCSK9<sup>-/-</sup> mice than in wt mice leading to the secretion of larger particles. Consistent with our results, LDLr-deficient mice present with increased postprandial lipemia after oil gavage compared to wt mice.<sup>25</sup> Furthermore, kinetic studies suggested that patients with familial hypercholesterolemia are

Comment citer ce document :

Le May, C, Kourimate, S., Langhi, C., Chetiveaux, M., Jarry, A., Comera, C., Collet, X., Kuipers, F., Krempf, M., Cariou, B., Costet, P. (2009). Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia, Arteriosclerosis, Thrombosis, and



**Figure 5.** Lipoprotein kinetics in PCSK9<sup>-/-</sup> mice. A, Hepatic TG contents 2 hours after the gavage (n=10 mice of each genotype). B, <sup>125</sup>I-labeled chylomicrons clearance. Data represent mean percentages of total <sup>125</sup>I clearance rate for each group ± SEM \*P<0.05, \*\*P<0.01, \*\*\*P<0.001.

characterized by an increased intestinal chylomicron production.<sup>26</sup> Our experiments also indicated a contribution from the liver to the reduced postprandial lipemia observed in PCSK9<sup>-/-</sup> mice. It is believed that chylomicron remnant clearance in mice is accountable for 75% of the LDLr, mainly in an apoE-dependent fashion.<sup>25</sup> Thus, it makes sense that PCSK9<sup>-/-</sup> mice that exhibit more LDLr clear their own remnants faster than wt mice. However, a hypothesis entirely based on an LDLr-dependent pathway is unsatisfactory given the fact that PCSK9<sup>-/-</sup> mice do not clear chylomicrons from wt mice significantly faster than control mice. It seems that there is a combination of specificities attributable to both the lack of hepatic PCSK9 and the nature of PCSK9<sup>-/-</sup> chylomicrons. We were unable to detect any difference between genotypes in chylomicron lipoprotein contents. They differed only by their larger size, together with a trend to a higher TG to PL ratio, suggesting that other factors may be at play. Future work will determine whether wt chylomicrons actually contain some PCSK9 protein that could interact with their clearance.

To summarize, we believe that the dramatic reduction of postprandial lipemia we observed in PCSK9<sup>-/-</sup> mice results from the combination of various effects, including the intestinal secretion of larger chylomicrons, and their higher hepatic clearance rate. We can only speculate that the intestinal LDLr plays a role in the reuptake of nascent particles. It is tempting to postulate that a specific intestinal

target of PCSK9 that is still to be discovered is involved. All together these results make postprandial kinetic investigations in human with partial or complete loss of PCSK9 highly desirable. We propose that PCSK9 inhibitors would help manage LDL cholesterol and also postprandial triglyceridemia, 2 important risk factors of cardiovascular disease.

### Acknowledgments

We thank Lucie Arnaud and Rick Havinga for their excellent technical help. The authors are grateful to Athina Kalopissis and Raphael Moriez for helpful discussions and to Joshua Musgrave for the correction of the manuscript.

### Sources of Funding

Funding for this research was obtained from the Agence Nationale de la Recherche (PNRA 2006 "ABSINTE"). C. Le May was supported by the Fondation pour la Recherche Médicale, Sanae Kourimate by Région Pays de la Loire and Centre de Recherche en Nutrition Humaine de Nantes, and Cédric Langhi by Nouvelle Société Française d'Athérosclérose. Philippe Costet is the titular of a "contrat d'interface CHU de Nantes-INSERM."

### Disclosures

None.

### References

1. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derre A, Villegier L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. *Nat Genet* 2003;34:154–156.
2. Horton JD, Cohen JC, Hobbs HH. Molecular biology of PCSK9: its role in LDL metabolism. *Trends Biochem Sci* 2007;32:71–77.
3. Zhang DW, Lagace TA, Garuti R, Zhao Z, McDonald M, Horton JD, Cohen JC, Hobbs HH. Binding of PCSK9 to EGF-A repeat of LDL receptor decreases receptor recycling and increases degradation. *J Biol Chem* 2007;282:18602–18612.
4. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. *N Engl J Med* 2006;354:1264–1272.
5. Cohen J, Pertsemliadis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. *Nat Genet* 2005;37:161–165.
6. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. *JAMA* 2007;298:309–316.
7. Nordestgaard BG, Benn M, Schnoh P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. *JAMA* 2007;298:299–308.
8. Rashid S, Curtis DE, Garuti R, Anderson NN, Bashmakov Y, Ho YK, Hammer RE, Moon YA, Horton JD. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. *Proc Natl Acad Sci U S A* 2005;102:5374–5379.
9. Mansbach CM, Gorelick F. Development and physiological regulation of intestinal lipid absorption. II. Dietary lipid absorption, complex lipid synthesis, and the intracellular packaging and secretion of chylomicrons. *Am J Physiol Gastrointest Liver Physiol* 2007;293:G645–G650.
10. Hayashi H, Fujimoto K, Cardelli JA, Nutting DF, Bergstedt S, Tso P. Fat feeding increases size, but not number, of chylomicrons produced by small intestine. *Am J Physiol* 1990;259:G709–G719.
11. Phillips ML, Pullinger C, Kroes I, Kroes J, Hardman DA, Chen G, Curtiss LK, Gutierrez MM, Kane JP, Schumaker VN. A single copy of apolipoprotein B-48 is present on the human chylomicron remnant. *J Lipid Res* 1997;38:1170–1177.
12. Lo CM, Nordskog BK, Nauli AM, Zheng S, Vonlehmden SB, Yang Q, Lee D, Swift LL, Davidson NO, Tso P. Why does the gut choose apolipoprotein B48 but not B100 for chylomicron formation? *Am J Physiol Gastrointest Liver Physiol* 2008;294:G344–G352.

Comment citer ce document :

Le May, C, Kourimate, S., Langhi, C., Chetiveaux, M., Jarry, A., Comera, C., Collet, X., Kuipers, F., Krempf, M., Cariou, B., Costet, P. (2009). Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia, Arteriosclerosis, Thrombosis, and

13. Martins IJ, Hone E, Chi C, Seydel U, Martins RN, Redgrave TG. Relative roles of LDLr and LRP in the metabolism of chylomicron remnants in genetically manipulated mice. *J Lipid Res.* 2000;41:205–213.
14. [Recommendations for cryopreservation of cells tumor tissues to be used for molecular analyses]. *Ann Pathol.* 2001;21:184–201.
15. French Bioethic Law No. 2004-800. 2008.
16. Deleted in proof.
17. Fong LG, Bonney E, Kosek JC, Cooper AD. Immunohistochemical localization of low density lipoprotein receptors in adrenal gland, liver, and intestine. *J Clin Invest.* 1989;84:847–856.
18. Dubuc G, Chamberland A, Wassef H, Davignon J, Seidah NG, Bernier L, Prat A. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. *Arterioscler Thromb Vasc Biol.* 2004;24:1454–1459.
19. Kourimate S, Le May C, Langhi C, Jarnoux AL, Ouguerram K, Zair Y, Nguyen P, Krempf M, Cariou B, Costet P. Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9. *J Biol Chem.* 2008;283:9666–9673.
20. Langhi C, Le May C, Kourimate S, Caron S, Staels B, Krempf M, Costet P, Cariou B. Activation of the farnesoid X receptor represses pcsk9 expression in human hepatocytes. *FEBS Lett.* 2008;19:949–955.
21. Fanous MY, Phillips AJ, Windsor JA. Mesenteric lymph: the bridge to future management of critical illness. *JOP.* 2007;8:374–399.
22. Graham MJ, Lemonidis KM, Whipple CP, Subramaniam A, Monia BP, Crooke ST, Crooke RM. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. *J Lipid Res.* 2007;48:763–767.
23. Greeve J, Altkemper I, Dieterich JH, Greten H, Windler E. Apolipoprotein B mRNA editing in 12 different mammalian species: hepatic expression is reflected in low concentrations of apoB-containing plasma lipoproteins. *J Lipid Res.* 1993;34:1367–1383.
24. Twisk J, Gillian-Daniel DL, Tebon A, Wang L, Barrett PH, Attie AD. The role of the LDL receptor in apolipoprotein B secretion. *J Clin Invest.* 2000;105:521–532.
25. Ishibashi S, Perrey S, Chen Z, Osuga J, Shimada M, Ohashi K, Harada K, Yazaki Y, Yamada N. Role of the low density lipoprotein (LDL) receptor pathway in the metabolism of chylomicron remnants. A quantitative study in knockout mice lacking the LDL receptor, apolipoprotein E, or both. *J Biol Chem.* 1996;271:22422–22427.
26. Tremblay AJ, Lamarche B, Ruel I, Hogue JC, Bergeron J, Gagne C, Couture P. Lack of evidence for reduced plasma apo B48 catabolism in patients with heterozygous familial hypercholesterolemia carrying the same null LDL receptor gene mutation. *Atherosclerosis.* 2004;172:367–373.